Current therapeutic landscape for advanced gastroesophageal cancers.

about

Current therapeutic landscape for advanced gastroesophageal cancers.

Item

http://www.wikidata.org/entity/Q52581752

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Current therapeutic landscape for advanced gastroesophageal cancers.

@en

Current therapeutic landscape for advanced gastroesophageal cancers.

@nl

type

Item

label

Current therapeutic landscape for advanced gastroesophageal cancers.

@en

Current therapeutic landscape for advanced gastroesophageal cancers.

@nl

prefLabel

Current therapeutic landscape for advanced gastroesophageal cancers.

@en

Current therapeutic landscape for advanced gastroesophageal cancers.

@nl

P1476

Current therapeutic landscape for advanced gastroesophageal cancers.

@en

P2093

Anthony Lopez

http://www.w3.org/2001/XMLSchema#string

Dilsa Mizrak Kaya

http://www.w3.org/2001/XMLSchema#string

Jaffer A Ajani

http://www.w3.org/2001/XMLSchema#string

Kazuto Harada

http://www.w3.org/2001/XMLSchema#string

P2860

Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-Analysis

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Global cancer statistics, 2012

The blockade of immune checkpoints in cancer immunotherapy

Comprehensive molecular characterization of gastric adenocarcinoma

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Trastuzumab--mechanism of action and use in clinical practice

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/ATM.2017.10.29

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29666801

http://www.w3.org/2001/XMLSchema#string

P932

5890037

http://www.w3.org/2001/XMLSchema#string